Johns Hopkins Clinical Research Study

HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (Version 3.0, dated 10/31/19) DAIDS Document ID: 20725

IRB Number: IRB00102211
Principal Investigator: Rompalo, Anne

Study Description:

Give PrEP a Shot!

You may be eligible for a research study that features:

-free and confidential HIV/STI testing

-free counseling and referrals

Learn more about HPTN 083, a research study comparing the effectiveness of injections and oral tablets to prevent HIV.


Eligibility Criteria:

-HIV negative

-A man (assigned male sex at birth) or a transgender woman who has sex with men

-Age 18 or older

-Able to attend study visits where HPTN 083 is being conducted

Recruitment Contact Name:Positive Choices Unit
Contact Phone:443-310-6738 (call or text)
Contact E-Mail: HPTNJHU@jhmi.edu

Location of Study Visits:

  • Johns Hopkins Hospital East Baltimore Campus

Study will provide compensation: Yes


  • HIV
  • Healthy Volunteers
  • Sex
  • Male
  • Men
  • Sexual Behavior
  • Injections
  • Sexually Transmitted Diseases